Epigenetic neural glioblastoma enhances synaptic integration and predicts therapeutic vulnerability.
BDNF
DIPG
DMG
GBM
Glioma
NPC
OPC
cancer neuroscience
connectivity
neuron
neuronal activity
stem cell
synapse
Journal
bioRxiv : the preprint server for biology
Titre abrégé: bioRxiv
Pays: United States
ID NLM: 101680187
Informations de publication
Date de publication:
07 Aug 2023
07 Aug 2023
Historique:
pubmed:
23
8
2023
medline:
23
8
2023
entrez:
23
8
2023
Statut:
epublish
Résumé
Neural-tumor interactions drive glioma growth as evidenced in preclinical models, but clinical validation is nascent. We present an epigenetically defined neural signature of glioblastoma that independently affects patients' survival. We use reference signatures of neural cells to deconvolve tumor DNA and classify samples into low- or high-neural tumors. High-neural glioblastomas exhibit hypomethylated CpG sites and upregulation of genes associated with synaptic integration. Single-cell transcriptomic analysis reveals high abundance of stem cell-like malignant cells classified as oligodendrocyte precursor and neural precursor cell-like in high-neural glioblastoma. High-neural glioblastoma cells engender neuron-to-glioma synapse formation
Identifiants
pubmed: 37609137
doi: 10.1101/2023.08.04.552017
pmc: PMC10441357
pii:
doi:
Types de publication
Preprint
Langues
eng
Subventions
Organisme : NCI NIH HHS
ID : U19 CA264504
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA258384
Pays : United States
Organisme : NINDS NIH HHS
ID : DP1 NS111132
Pays : United States
Organisme : NINDS NIH HHS
ID : R01 NS092597
Pays : United States
Organisme : NCI NIH HHS
ID : R21 CA264339
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA097257
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA165962
Pays : United States
Organisme : NINDS NIH HHS
ID : K08 NS110919
Pays : United States
Déclaration de conflit d'intérêts
Competing Interests M.L.S. is equity holder, scientific co-founder and advisory board member of Immunitas Therapeutics. M.M. holds equity in MapLight Therapeutics.